Regencell Bioscience (NASDAQ:RGC) Stock Price Down 6.7% – Here’s What Happened

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price was down 6.7% during mid-day trading on Thursday . The company traded as low as $22.31 and last traded at $22.15. Approximately 45,239 shares changed hands during mid-day trading, a decline of 84% from the average daily volume of 291,052 shares. The stock had previously closed at $23.75.

More Regencell Bioscience News

Here are the key news stories impacting Regencell Bioscience this week:

• Neutral Sentiment: Multiple law firms, including Rosen Law Firm, Robbins LLP, Faruqi & Faruqi, The Gross Law Firm, Bragar Eagel & Squire, and Pomerantz, issued or repeated notices about a pending class action and the June 23, 2026 lead plaintiff deadline. Article Title
• Neutral Sentiment: The lawsuits allege that investors who bought RGC shares during the class period may have been harmed and could be eligible to seek compensation, adding legal overhang and uncertainty for the stock. Article Title
• Negative Sentiment: The complaint references alleged disclosure and valuation concerns, including claims that the company’s high valuation was supported by limited revenue and a small workforce, which may be fueling investor concern and selling pressure. Article Title

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Regencell Bioscience in a research note on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Regencell Bioscience Trading Down 9.8%

The company has a 50-day moving average price of $27.42 and a two-hundred day moving average price of $25.35.

Regencell Bioscience (NASDAQ:RGC) last released its earnings results on Friday, May 8th. The company reported $0.00 earnings per share for the quarter.

Hedge Funds Weigh In On Regencell Bioscience

Several large investors have recently modified their holdings of RGC. Seven Fleet Capital Management LP bought a new position in shares of Regencell Bioscience during the 4th quarter valued at approximately $92,000. Amundi purchased a new position in Regencell Bioscience during the 1st quarter valued at $219,000. Hudson Bay Capital Management LP purchased a new position in Regencell Bioscience during the 4th quarter valued at $275,000. Bank of America Corp DE boosted its holdings in Regencell Bioscience by 59,113.8% during the 1st quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after acquiring an additional 17,143 shares during the period. Finally, XTX Topco Ltd purchased a new position in Regencell Bioscience during the 3rd quarter valued at $598,000. Institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.